Oceanpine Capital

Founded 2017
Founders David Liguang Chenn

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 14
Average round size
info
The average size of a deal this fund participated in
$196M
Portfolio companies 17
Rounds per year 3.50
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.07
Exits 1
Key employees 1
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Biopharma
  • Pharmaceutical
  • Machine Learning
Summary

Oceanpine Capital appeared to be the VC, which was created in 2017. The company was established in Asia in Hong Kong. The main office of represented VC is situated in the Central.

We can highlight the next thriving fund investment areas, such as Oil and Gas, Semiconductor. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 3 of the founder, the chance for it to get the investment is meager. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Horizon Robotics, Tiger Brokers, 51zhaoyou.com. For fund there is no match between the location of its establishment and the land of its numerous investments - China.

The average startup value when the investment from Oceanpine Capital is more than 1 billion dollars. The usual things for fund are deals in the range of more than 100 millions dollars. The fund is generally included in 2-6 deals every year. The top activity for fund was in 2018. The increased amount of exits for fund were in 2019. Opposing the other organizations, this Oceanpine Capital works on 9 percentage points less the average amount of lead investments.

The standard case for the fund is to invest in rounds with 7-8 partakers. Despite the Oceanpine Capital, startups are often financed by ZhenFund, Yunqi Partners, Wu Capital. The meaningful sponsors for the fund in investment in the same round are Matrix Partners China, Lilly Asia Ventures, 3E Bioventures. In the next rounds fund is usually obtained by Matrix Partners China, Lilly Asia Ventures, Korea Investment Partners.

The fund was created by David Liguang Chenn Chenn. Besides them, we counted 1 critical employee of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Oceanpine Capital:
Typical Co-investors
Oceanpine Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Oceanpine Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from China, Hong Kong Island
Funds with similar focus located in China, Hong Kong Island:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Axioma Ventures United States, Green Bay
30Ventures United States, Madison
Kejora Ventures Indonesia, Jakarta
MetaBrand Capital United States, Edison
Posco South Korea, Seoul
SND Ventures Group China, Suzhou
Simpleweb United Kingdom, Bristol
Loeb Enterprises United States, New York
Orient Securities China, Shanghai
CIT VentureCapital United States, Morristown
Vision Knight Capital China, Shanghai
Soul Capital New Zealand, Auckland
BlueCap Partners United States, Austin
Burrill Agbio Capital Fund United States, San Francisco
TI Holdings -
Epilepsy United States, Maryland
SEN CORPORATION Japan Japan, Tokyo
Yipu Capital -
2500 Bachman Ventures United States, Atlanta
Caterpillar Foundation -

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Svolt Energy Technology Co.

Battery
Electric Vehicle
Energy
Energy Storage
Manufacturing
1
$1B01 Aug 2021 China, Baoding City

Biopharma
Biotechnology
Health Care
Medical
Therapeutics
1
$73M30 Mar 2021 United States, Palo Alto

Yisheng Biopharma

Biopharma
Biotechnology
1
$130M24 Feb 2021 China, Dongcheng District

Teon Therapeutics

Biopharma
Biotechnology
Pharmaceutical
1
$30M23 Feb 2021 United States, Redwood City

Clover Biopharmaceuticals

Biotechnology
Clinical Trials
Health Care
Pharmaceutical
1
$230M22 Feb 2021 China, Qingyang District

Creative Biosciences

Biopharma
Biotechnology
Health Care
1
$92M27 Sep 2020 China, Yuexiu District

Triumvira Immunologics

Biotechnology
Clinical Trials
Health Care
1
$55M27 Aug 2020 United States, Austin

Biotechnology
Life Science
1
$154M25 Aug 2020 China, Gusu District

Hiretual

Artificial Intelligence
Big Data
Employment
Human Resources
Machine Learning
Recruiting
SaaS
Software
1
$13M13 Aug 2020 United States, Mountain View
News
SVOLT Energy Closes RMB10.28 Billion Series B Financing

– SVOLT Energy Technology Co., Ltd. is a Beijing, China-based EV battery manufacturer.
– Company raised a total amount of RMB 10.28 billion ($US 1.58 billion) in Series B funding.
– The round was led by Bank of China Group Investment (BOCGI), Country Garden Venture Capital, Shenzhen Capital Group (SCGC), CCB Investment, IDG Capital, Sany, Xiaomi Corporation, Oceanpine Capital, CHINA RENAISSANCE among others.
– The Series B funds will be mainly used for R&D of new technologies and construction of new factories.

Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors

– Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints today announced the closing of a $73 million Series B1 and B2 financing.
– The round was led by Oceanpine Capital with participation from additional new investors including Octagon Capital and Sphera Healthcare, and existing investors, including Northern Light Venture Capital and Vivo Capital.
– In conjunction with this round of financing, Oceanpine CEO and managing partner Dave Chenn joins the Immune-Onc Board of Directors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Oceanpine Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: